A Phase 4 interventional study of atorvastatin and IVUS/OCT in Plaque, Atherosclerotic, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 19 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Plaque, Atherosclerotic with a site in China — 7 open to participants now, 9 under way, 2 of them phase 3. Plaque, Atherosclerotic · China.
Among the 13 studies in Plaque, Atherosclerotic with a site in China, this one is the only one that started in 2024, is one of 3 in phase 4, and was the 9th registered.
105 studies on the registry are indexed under Plaque, Atherosclerotic; 27 are open to participants now.
Browse Plaque, Atherosclerotic studies →7 of the 13 studies in Plaque, Atherosclerotic with a site in China are open now. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–80
jiaoliqun · Sites in China
Ages 18+
Jinling Hospital, China · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 30–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 16 Plaque, Atherosclerotic studies recruiting now, 7 (44%) set no upper age limit and 4 (25%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 318 is above the median of 160 across 51 interventional studies indexed under Plaque, Atherosclerotic.
Median enrollment 254 across the 8 interventional studies, 400 across the 5 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Plaque, Atherosclerotic — fewer than ten, so there is no comparison to draw.
4 of the studies in Plaque, Atherosclerotic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06372925Novartis PharmaceuticalsIntravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction | 2026-12-30 |
| NCT06025305Jinling Hospital, ChinaIdentifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography | 2026-12-31 |
| NCT05550077jiaoliqunOptical Coherence Tomography for Intracranial Atherosclerotic Stenosis | 2026-12-31 |
| NCT07680595Ruijin HospitalProspective Management of Plaque Instability With Statins and Extra Folic Acid | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Plaque, Atherosclerotic with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density lipoprotein cholesterol (LDL-C).
This study will be a multi-center, randomized, parallel-group, open-label, phase 4 study. Participants will be Chinese adults diagnosed with new-onset STEMI/NSTEMI and elevated LDL-C (LDL-C > 1.8 mmol/L if on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks; LDL-C > 2.6 mmol/L if not on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks). Participants will be 1:1 randomized to investigational group (Inclisiran 284mg + 20mg atorvastatin) or control group (20mg atorvastatin) for 360 days. Participants and investigator will be unblinded to the identity of the treatment from the time of randomization. Independent Review Committee (IRC) staff performing the study assessments (IVUS and OCT analysis) will be blinded to the identity of the treatment from the time of randomization until final database lock.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Presence of atherosclerotic plaque with ≥ 20% and ≤ 50% diameter stenosis by coronary angiography.
2) Target vessel deemed to be accessible to imaging catheters and suitable for intravascular imaging in the proximal (50 mm) segment ("target segment") 3) Target vessel is suitable for IVUS and OCT evaluation. 4) Not have undergone previous PCI within target vessel. 5) Not be a bypass graft or a bypassed native vessel. 4. Rapid LDL-C test value at screening period of:
5. Written must be obtained.
Exclusion Criteria:
1) Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening; 2) Pacemaker or ICD in situ; and/or 3) Uncontrolled severe hypertension with systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite antihypertensive therapy.
11. Rapid lipid test triglyceride (TG) level > 400mg/dL (4.5 mmol/L) at screening.
12. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in (ALT), aspartate aminotransferase (AST), > 3x the (ULN), or total > 2x ULN before the randomization.
13. Estimated (eGFR) \< 30 mL/min/1.73m2(Calculated according to the modified MDRD equation).
14. Severe concomitant non-cardiovascular disease that carries the risk of reducing to less than 2 years.
15. Previous (within 90 days before randomization), current or planned treatment with a PCSK9 monoclonal antibody (mAb).
16. Previous exposure to Inclisiran or any other non-mAb PCSK9-targeted therapy 2 years prior to randomization.
17. Participation in another device or drug study currently, or within 5 half-live (if drug) or 30 days whichever is longer, prior to randomization.
18. History of to any study drug or its . 19. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study and/or put the participant at significant risk according to investigator's judgment.
20. Pregnant or nursing (lactating) women. 21. Women of , unless they are using effective methods of during study treatment.
22. Any conditions that according to the investigator could interfere with the conduct of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran 284mg SC (at D1,D90,D270)+ 20mg atorvastatin PO
Drug: atorvastatin · Procedure: IVUS/OCT · Drug: inclisiran
20mg atorvastatin PO
Drug: atorvastatin · Procedure: IVUS/OCT
20mg atorvastatin PO
performed the IVUS/OCT at baseline and Day 360
Inclisiran 284mg SC
Change in percent atheroma volume (PAV)
Change in PAV assessed by intravascular ultrasound (IVUS) from baseline to Day 360.
Time frame: Up to 360 days
Change in minimum fibrous cap thickness (FCT)
Change in minimum FCT as determined by optical coherence tomography (OCT) from baseline to Day 360
Time frame: Up to 360 days
Change in mean minimum FCT of all images
Change in mean minimum fibrous cap thickness (FCT) of all images as determined by OCT from baseline to Day 360.
Time frame: 360 days
Change in normalized total atheroma volume (NTAV)
Change in NTAV as determined by intravascular ultrasound (IVUS) from baseline to Day 360
Time frame: Up to 360 days
Proportion of participants with progression, regression, or no change in PAV
Proportion of participants with progression, regression, or no change in percent atheroma volume (PAV) at Day 360
Time frame: Up to 360 days
Change in LDL-C
Change in low-density lipoprotein cholesterol (LDL-C)
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in TC
Change in total cholesterol (TC).
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in HDL-C
Change in high-density lipoprotein cholesterol (HDL-C).
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in non-HDL-C
Change in non-high-density lipoprotein cholesterol (non-HDL-C).
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in ApoB
Change in apolipoprotein B (ApoB).
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in ApoA1
Change in apolipoprotein A1 (ApoA1).
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in Lp(a)
Change in lipoprotein (a) (Lp(a))
Time frame: Baseline, Day 30, Day 150 and Day 360
Change in TG
Change in triglycerides (TG)
Time frame: Baseline, Day 30, Day 150 and Day 360
Proportion of participants with LDL-C target attainment
Proportion of participants with LDL-C target attainment at Day 30, Day 150, and Day 360
Time frame: Day 30, Day 150 and Day 360
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran